KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Share-based Compensation: 2018-2024

Historic Share-based Compensation for Amneal Pharmaceuticals (AMRX) over the last 7 years, with Dec 2024 value amounting to $27.8 million.

  • Amneal Pharmaceuticals' Share-based Compensation rose 15.57% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year increase of 16.69%. This contributed to the annual value of $27.8 million for FY2024, which is 3.53% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Share-based Compensation stood at $27.8 million for FY2024, which was up 3.53% from $26.8 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Share-based Compensation ranged from a high of $31.8 million in FY2022 and a low of $20.8 million during FY2020.
  • In the last 3 years, Amneal Pharmaceuticals' Share-based Compensation had a median value of $27.8 million in 2024 and averaged $28.8 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first spiked by 36.93% in 2021, then fell by 15.78% in 2023.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Share-based Compensation stood at $20.8 million in 2020, then spiked by 36.93% to $28.4 million in 2021, then rose by 12.09% to $31.8 million in 2022, then fell by 15.78% to $26.8 million in 2023, then increased by 3.53% to $27.8 million in 2024.